Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-d9a2d4a9aed73e1deb35a60f1ae8a7b2",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-d9a2d4a9aed73e1deb35a60f1ae8a7b2",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-d9a2d4a9aed73e1deb35a60f1ae8a7b2",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-d9a2d4a9aed73e1deb35a60f1ae8a7b2\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-d9a2d4a9aed73e1deb35a60f1ae8a7b2</b></p><a name=\"composition-en-d9a2d4a9aed73e1deb35a60f1ae8a7b2\"> </a><a name=\"hccomposition-en-d9a2d4a9aed73e1deb35a60f1ae8a7b2\"> </a><a name=\"composition-en-d9a2d4a9aed73e1deb35a60f1ae8a7b2-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/18/1281/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - kanjinti</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/18/1281/001"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mpd9a2d4a9aed73e1deb35a60f1ae8a7b2"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - kanjinti",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What KANJINTI is and what it is used for</li><li>What you need to know before you are given KANJINTI</li><li>How KANJINTI is given</li><li>Possible side effects</li><li>How to store KANJINTI</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What kanjinti is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What kanjinti is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>KANJINTI contains the active substance trastuzumab, which is a monoclonal antibody. Monoclonal antibodies attach to specific proteins or antigens. Trastuzumab is designed to bind selectively to an antigen called human epidermal growth factor receptor 2 (HER2). HER2 is found in large amounts on the surface of some cancer cells where it stimulates their growth. When trastuzumab binds to HER2 it stops the growth of such cells and causes them to die.</p><p>Your doctor may prescribe KANJINTI for the treatment of breast and gastric cancer when:</p><ul><li>You have early breast cancer, with high levels of a protein called HER2. * You have metastatic breast cancer (breast cancer that has spread beyond the original tumour) with high levels of HER2. KANJINTI may be prescribed in combination with the chemotherapy medicine paclitaxel or docetaxel as first treatment for metastatic breast cancer or it may be prescribed alone if other treatments have proved unsuccessful. It is also used in combination with medicines called aromatase inhibitors with patients with high levels of HER2 and hormone-receptor positive metastatic breast cancer (cancer that is sensitive to the presence of female sex hormones).</li><li>You have metastatic gastric cancer with high levels of HER2, when it is in combination with the other cancer medicines capecitabine or 5-fluorouracil and cisplatin.</li></ul></div>"
}
},
{
"title" : "2. What you need to know before you take kanjinti",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take kanjinti"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not use KANJINTI if:</p><ul><li>you are allergic to trastuzumab, to murine (mouse) proteins, or to any of the other ingredients of this medicine (listed in section 6).</li><li>you have severe breathing problems at rest due to your cancer or if you need oxygen treatment.</li></ul><p>Warnings and precautions Your doctor will closely supervise your therapy.</p><p>Heart checks Treatment with KANJINTI alone or with a taxane may affect the heart, especially if you have ever used an anthracycline (taxanes and anthracyclines are two other kinds of medicine used to treat cancer). The effects may be moderate to severe and could cause death. Therefore, your heart function will be checked before, during (every three months) and after (up to two to five years) treatment with KANJINTI. If you develop any signs of heart failure (inadequate pumping of blood by the heart), your heart function may be checked more frequently (every six to eight weeks), you may receive treatment for heart failure or you may have to stop KANJINTI treatment.</p><p>Talk to your doctor, pharmacist or nurse before you are given KANJINTI if:</p><ul><li>you have had heart failure, coronary artery disease, heart valve disease (heart murmurs), high blood pressure, taken any high blood pressure medicine or are currently taking any high blood pressure medicine.</li><li>you have ever had or are currently using a medicine called doxorubicin or epirubicin (medicines used to treat cancer). These medicines (or any other anthracyclines) can damage heart muscle and increase the risk of heart problems with KANJINTI.</li><li>you suffer from breathlessness, especially if you are currently using a taxane. KANJINTI can cause breathing difficulties, especially when it is first given. This could be more serious if you are already breathless. Very rarely, patients with severe breathing difficulties before treatment have died when they were given trastuzumab.</li><li>you have ever had any other treatment for cancer.</li></ul><p>If you receive KANJINTI with any other medicine to treat cancer, such as paclitaxel, docetaxel, an aromatase inhibitor, capecitabine, 5-fluorouracil, or cisplatin you should also read the patient information leaflets for these products.</p><p>Children and adolescents KANJINTI is not recommended for anyone under the age of 18 years.</p><p>Other medicines and KANJINTI Tell your doctor, pharmacist or nurse if you are taking, have recently taken or may take any other medicines.</p><p>It may take up to 7 months for KANJINTI to be removed from the body. Therefore, you should tell your doctor, pharmacist or nurse that you have had KANJINTI if you start any new medicine in the 7 months after stopping treatment.</p><p>Pregnancy</p><ul><li>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.</li><li>You should use effective contraception during treatment with KANJINTI and for at least 7 months after KANJINTI treatment has ended.</li><li>Your doctor will advise you of the risks and benefits of taking KANJINTI during pregnancy. In rare cases, a reduction in the amount of (amniotic) fluid that surrounds the developing baby within the womb has been observed in pregnant women receiving trastuzumab. This condition may be harmful to your baby in the womb and has been associated with the lungs not developing fully resulting in foetal death.</li></ul><p>Breast-feeding Do not breast-feed your baby during KANJINTI therapy and for 7 months after the last dose, as KANJINTI may pass to your baby through your breast milk.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>Driving and using machines KANJINTI may affect your ability to drive a car or use machines. If during treatment you experience symptoms, such as dizziness, sleepiness, chills or fever, you should not drive or use machines until these symptoms disappear.</p><p>Sodium This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium-free .</p></div>"
}
},
{
"title" : "3. How to take kanjinti",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take kanjinti"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Before starting the treatment your doctor will determine the amount of HER2 in your tumour. Only patients with a large amount of HER2 will be treated with KANJINTI. KANJINTI should only be given by a doctor or nurse. Your doctor will prescribe a dose and treatment regimen that is right for you. The dose of KANJINTI depends on your body weight.</p><p>It is important to check the product labels to ensure that the correct formulation is being given as prescribed. KANJINTI intravenous formulation is not for subcutaneous use and should be given as an intravenous infusion only.</p><p>KANJINTI intravenous formulation is given as an intravenous infusion ( drip ) directly into your veins. The first dose of your treatment is given over 90 minutes and you will be observed by a health professional while it is being given in case you have any side effects. If the first dose is well tolerated the next doses may be given over 30 minutes (see section 2 under Warnings and precautions ). The number of infusions you receive will depend on how you respond to the treatment. Your doctor will discuss this with you.</p><p>In order to prevent medication errors it is important to check the vial labels to ensure that the medicine being prepared and given is KANJINTI (trastuzumab) and not another trastuzumab-containing product (e.g. trastuzumab emtansine or trastuzumab deruxtecan).</p><p>For early breast cancer, metastatic breast cancer and metastatic gastric cancer, KANJINTI is given every 3 weeks. KANJINTI may also be given once a week for metastatic breast cancer.</p><p>If you stop using KANJINTI Do not stop using this medicine without talking to your doctor first. All doses should be taken at the right time every week or every three weeks (depending on your dosing schedule). This helps your medicine work as well as it can.</p><p>It may take up to 7 months for KANJINTI to be removed from your body. Therefore your doctor may decide to continue to check your heart functions, even after you finish treatment.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, KANJINTI can cause side effects, although not everybody gets them. Some of these side effects may be serious and may lead to hospitalisation.</p><p>During a KANJINTI infusion, chills, fever and other flu like symptoms may occur. These are very common (may affect more than 1 in 10 people). Other infusion-related symptoms are: feeling sick (nausea), vomiting, pain, increased muscle tension and shaking, headache, dizziness, breathing difficulties, high or low blood pressure, heart rhythm disturbances (palpitations, heart fluttering or irregular heart beat), swelling of the face and lips, rash and feeling tired. Some of these symptoms can be serious and some patients have died (see section 2 under Warnings and precautions ).</p><p>These effects mainly occur with the first intravenous infusion ( drip into your vein) and during the first few hours after the start of the infusion. They are usually temporary. You will be observed by a health care professional during the infusion and for at least six hours after the start of the first infusion and for two hours after the start of other infusions. If you develop a reaction, they will slow down or stop the infusion and may give you treatment to counteract the side effects. The infusion may be continued after the symptoms improve.</p><p>Occasionally, symptoms start later than six hours after the infusion begins. If this happens to you, contact your doctor immediately. Sometimes, symptoms may improve and then get worse later.</p><p>Serious side effects Other side effects can occur at any time during treatment with trastuzumab, not just related to an infusion. Tell a doctor or nurse straight away, if you notice any of the following side effects:</p><ul><li>Heart problems can sometimes occur during treatment and occasionally after treatment has stopped and can be serious. They include weakening of the heart muscle possibly leading to heart failure, inflammation of the lining around the heart and heart rhythm disturbances. This can lead to symptoms such as breathlessness (including breathlessness at night), cough, fluid retention (swelling) in the legs or arms, palpitations (heart fluttering or irregular heart beat) (see section 2. Heart checks).</li></ul><p>Your doctor will monitor your heart regularly during and after treatment but you should tell your doctor immediately if you notice any of the above symptoms.</p><ul><li>Tumour lysis syndrome (a group of metabolic complications occurring after cancer treatment characterised by high blood levels of potassium and phosphate, and low blood levels of calcium). Symptoms may include kidney problems (weakness, shortness of breath, fatigue and confusion), heart problems (fluttering of the heart or a faster or slower heartbeat), seizures, vomiting or diarrhoea and tingling in the mouth, hands or feet.</li></ul><p>If you experience any of the above symptoms when your treatment with KANJINTI has finished, you should see your doctor and tell them that you have previously been treated with KANJINTI.</p><p>Other side effects</p><p>Very common side effects (may affect more than 1 in 10 people):</p><ul><li><p>infections</p></li><li><p>diarrhoea</p></li><li><p>constipation</p></li><li><p>heartburn (dyspepsia)</p></li><li><p>fatigue</p></li><li><p>skin rashes</p></li><li><p>chest pain</p></li><li><p>abdominal pain</p></li><li><p>joint pain</p></li><li><p>low counts of red blood cells and white blood cells (which help fight infection) sometimes with fever</p></li><li><p>muscle pain</p></li><li><p>conjunctivitis</p></li><li><p>watery eyes</p></li><li><p>nose bleeds</p></li><li><p>runny nose</p></li><li><p>hair loss</p></li><li><p>tremor</p></li><li><p>hot flush</p></li><li><p>dizziness</p></li><li><p>nail disorders</p></li><li><p>weight loss</p></li><li><p>loss of appetite</p></li><li><p>inability to sleep (insomnia)</p></li><li><p>altered taste</p></li><li><p>low platelet count</p></li><li><p>bruising</p></li><li><p>numbness or tingling of the fingers and toes, which occasionally may extend to the rest of the limb</p></li><li><p>redness, swelling or sores in your mouth and/or throat</p></li><li><p>pain, swelling, redness or tingling of hands and/or feet</p></li><li><p>breathlessness</p></li><li><p>headache</p></li><li><p>cough</p></li><li><p>vomiting</p></li><li><p>nausea</p></li></ul><p>Common side effects (may affect up to 1 in 10 people):</p><ul><li>allergic reactions</li><li>throat infections</li><li>bladder and skin infections</li><li>inflammation of the breast</li><li>inflammation of the liver</li><li>kidney disorders</li><li>increased muscle tone or tension</li></ul><p>(hypertonia)</p><ul><li>pain in the arms and/or legs</li><li>itchy rash</li><li>sleepiness (somnolence)</li><li>haemorrhoids</li><li>itchiness</li><li>dry mouth and skin</li><li>dry eyes</li><li>sweating</li><li>feeling weak and unwell</li><li>anxiety</li><li>depression</li><li>asthma</li><li>infection of lungs</li><li>lung disorders</li><li>back pain</li><li>neck pain</li><li>bone pain</li><li>acne</li><li>leg cramps</li></ul><p>Uncommon side effects (may affect up to 1 in 100 people):</p><ul><li>deafness</li><li>bumpy rash</li><li>wheezing</li><li>inflammation or scarring of the lungs</li></ul><p>Rare side effects (may affect up to 1 in 1 000 people):</p><ul><li>jaundice</li><li>anaphylactic reactions</li></ul><p>Side effects with unknown frequency (frequency cannot be estimated from the available data):</p><ul><li><p>abnormal or impaired blood clotting</p></li><li><p>high potassium levels</p></li><li><p>swelling or bleeding at the back of the eyes</p></li><li><p>shock</p></li><li><p>abnormal heart rhythm</p></li><li><p>respiratory distress</p></li><li><p>respiratory failure</p></li><li><p>acute accumulation of fluid in the lungs</p></li><li><p>acute narrowing of the airways</p></li><li><p>abnormally low oxygen levels in the blood</p></li><li><p>difficulty in breathing when lying flat</p></li><li><p>liver damage</p></li><li><p>swelling of the face, lips and throat</p></li><li><p>kidney failure</p></li><li><p>abnormally low levels of fluid around baby in womb</p></li><li><p>failure of the lungs of the baby to develop in the womb</p></li><li><p>abnormal development of the kidneys of the baby in the womb</p></li></ul><p>Some of the side effects you experience may be due to your underlying cancer. If you receive KANJINTI in combination with chemotherapy, some of them may also be due to the chemotherapy.</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse.</p><p>Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store kanjinti",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store kanjinti"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>KANJINTI will be stored by the health professionals at the hospital or clinic.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the outer carton and on the vial label after EXP. The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2 C - 8 C). Do not freeze the reconstituted solution. Store in the original package in order to protect from light.</p><p>Infusion solutions should be used immediately after dilution. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user, and would not normally be longer than 24 hours at 2 C - 8 C. Do not use KANJINTI if you notice any particulate matter or discolouration prior to administration.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What KANJINTI contains</p><ul><li>The active substance is trastuzumab. Each vial contains either: 150 mg trastuzumab that has to be dissolved in 7.2 mL of water for injection, or<br/>420 mg trastuzumab that has to be dissolved in 20 mL of water for injection.</li><li>The resulting solution contains approximately 21 mg/mL trastuzumab.</li><li>The other ingredient(s) are histidine, histidine monohydrochloride, trehalose dihydrate, polysorbate 20. What KANJINTI looks like and contents of the pack KANJINTI is a powder for concentrate for solution, which is supplied in a glass vial with a rubber stopper containing either 150 mg or 420 mg of trastuzumab. The powder is a white to pale yellow pellet. Each carton contains 1 vial of powder.</li></ul><p>Marketing Authorisation Holder and Manufacturer Amgen Europe B.V. Minervum 7NL-4817 ZK Breda The Netherlands</p><p>Marketing Authorisation Holder Amgen Europe B.V. Minervum 7NL-4817 ZK Breda The Netherlands</p><p>Manufacturer<br/>Amgen NV Telecomlaan 5-7 1831 Diegem Belgium</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien s.a. Amgen n.v. Tel/T l: +32 (0)2 7752Lietuva Amgen Switzerland AG Vilniaus filialas Tel: +370 5 219 7</p><p>.: +359 (0)2 424 7Luxembourg/Luxemburg s.a. Amgen<br/>Belgique/Belgien Tel/T l: +32 (0)2 7752 esk republika Amgen s.r.o. Tel: +420 221 773 Magyarorsz g Amgen Kft. Tel.: +36 1 35 44 Danmark Amgen, filial af Amgen AB, Sverige Tlf: +45 39617Malta Amgen S.r.l. Tel: +39 02 6241Deutschland Amgen GmbH Tel.: +49 89 1490Nederland Amgen B.V. Tel: +31 (0)76 5732Eesti Amgen Switzerland AG Vilniaus filialas Tel: +372 586 09Norge Amgen AB Tel: +47 23308<br/>Amgen . . .<br/>.: +30 210 3447 sterreich Amgen GmbH<br/>Tel: +43 (0)1 50 Espa a Amgen S.A. Tel: +34 93 600 18 Polska Amgen Biotechnologia Sp. z o.o. Tel.: +48 22 581 3France Amgen S.A.S. T l: +33 (0)9 69 363 Portugal Amgen Biofarmac utica, Lda. Tel: +351 21 4220Hrvatska Amgen d.o.o. Tel: +385 (0)1 562 57 Rom nia Amgen Rom nia SRL Tel: +4021 527 3Ireland Amgen Ireland Limited Tel: +353 1 8527Slovenija AMGEN zdravila d.o.o. Tel: +386 (0)1 585 1 sland Vistor hf. S mi: +354 535 7Slovensk republika Amgen Slovakia s.r.o. Tel: +421 2 321 114 Italia Amgen S.r.l. Tel: +39 02 6241Suomi/Finland Amgen AB, sivuliike Suomessa/Amgen AB, filial i Finland Puh/Tel: +358 (0)9 54900K<br/>C.A. Papaellinas Ltd .: +357 22741 Sverige Amgen AB<br/>Tel: +46 (0)8 6951Latvija Amgen Switzerland AG R gas fili le Tel: +371 257 25United Kingdom (Northern Ireland) Amgen Limited Tel: +44 (0)1223 420This leaflet was last revised in</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mpd9a2d4a9aed73e1deb35a60f1ae8a7b2",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mpd9a2d4a9aed73e1deb35a60f1ae8a7b2",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mpd9a2d4a9aed73e1deb35a60f1ae8a7b2\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mpd9a2d4a9aed73e1deb35a60f1ae8a7b2</b></p><a name=\"mpd9a2d4a9aed73e1deb35a60f1ae8a7b2\"> </a><a name=\"hcmpd9a2d4a9aed73e1deb35a60f1ae8a7b2\"> </a><a name=\"mpd9a2d4a9aed73e1deb35a60f1ae8a7b2-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/18/1281/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: KANJINTI 150 mg powder for concentrate for solution for infusion</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/18/1281/001"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "KANJINTI 150 mg powder for concentrate for solution for infusion",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
